BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tellado JM, Wilson SE. Empiric Treatment of Nosocomial Intra-Abdominal Infections: A Focus on the Carbapenems. Surgical Infections 2005;6:329-43. [DOI: 10.1089/sur.2005.6.329] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 De Fera A, Zummo S, Sarro M. In Vitro Activity Studies of Doripenem and Two Other Carbapenems Tested Against Pseudomonas aeruginosa and Other Non-Fermentative Bacilli. Journal of Chemotherapy 2013;23:335-40. [DOI: 10.1179/joc.2011.23.6.335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ikawa K, Morikawa N, Sakamoto K, Ikeda K, Ohge H, Takesue Y, Sueda T. Pharmacokinetics and Pharmacodynamic Assessment of Imipenem in the Intraperitoneal Fluid of Abdominal Surgery Patients. Chemotherapy 2008;54:131-9. [DOI: 10.1159/000118665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
3 Masterton RG. The new treatment paradigm and the role of carbapenems. International Journal of Antimicrobial Agents 2009;33:105.e1-8. [DOI: 10.1016/j.ijantimicag.2008.07.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
4 Morris JA Jr, Fildes J, May AK, Diaz J, Britt LD, Meredith JW; American Association for the Surgery of Trauma’s EGS Research Agenda Committee. A research agenda for emergency general surgery: clinical trials. J Trauma Acute Care Surg 2013;74:329-33. [PMID: 23271107 DOI: 10.1097/TA.0b013e31827542cd] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
5 Chandra A, Dhar P, Dharap S, Goel A, Gupta R, Hardikar JV, Kapoor VK, Mathur AK, Modi P, Narwaria M, Ramesh MK, Ramesh H, Sastry R, Shah S, Virk S, Sudheer OV, Sreevathsa MR, Varshney S, Kochhar P, Somasundaram S, Desai C, Schou M; Mascot Study Group. Cefoperazone-Sulbactam for Treatment of Intra-Abdominal Infections: Results from a Randomized, Parallel Group Study in India. Surgical Infections 2008;9:367-76. [DOI: 10.1089/sur.2007.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Mayne D, Dowzicky MJ. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009). Diagn Microbiol Infect Dis 2012;74:151-7. [PMID: 22770774 DOI: 10.1016/j.diagmicrobio.2012.05.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Mohr JF 3rd. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008;47 Suppl 1:S41-51. [PMID: 18713049 DOI: 10.1086/590065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
8 Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opin Pharmacother 2007;8:167-82. [PMID: 17257087 DOI: 10.1517/14656566.8.2.167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
9 Brook I. Treatment of anaerobic infection. Expert Rev Anti Infect Ther 2007;5:991-1006. [PMID: 18039083 DOI: 10.1586/14787210.5.6.991] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
10 Mazuski JE. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007;8:2933-45. [PMID: 18001254 DOI: 10.1517/14656566.8.17.2933] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
11 Tori K, Tansarli GS, Parente DM, Kalligeros M, Ziakas PD, Mylonakis E. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model. Medicine (Baltimore) 2020;99:e20022. [PMID: 32443305 DOI: 10.1097/MD.0000000000020022] [Reference Citation Analysis]
12 Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T, Taniwaki M, Kurisu K. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. Journal of Infection and Chemotherapy 2010;16:25-32. [DOI: 10.1007/s10156-009-0022-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
13 Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect 2008;14:1102-11. [PMID: 19076841 DOI: 10.1111/j.1469-0691.2008.02101.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
14 Brook I. Antimicrobial treatment of anaerobic infections. Expert Opinion on Pharmacotherapy 2011;12:1691-707. [DOI: 10.1517/14656566.2011.576672] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
15 Baughman RP. The use of carbapenems in the treatment of serious infections. J Intensive Care Med. 2009;24:230-241. [PMID: 19617229 DOI: 10.1177/0885066609335660] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
16 Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clinical Therapeutics 2008;30:868-83. [DOI: 10.1016/j.clinthera.2008.04.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
17 Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008;9:23-37. [PMID: 18076336 DOI: 10.1517/14656566.9.1.23] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 8.0] [Reference Citation Analysis]
18 Sader HS, Castanheira M, Flamm RK, Huband MD, Jones RN. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014. Surg Infect (Larchmt) 2016;17:473-8. [PMID: 27104633 DOI: 10.1089/sur.2016.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]